| |
| | Sloan-Kettering - Laboratory of William Pao: Publications |
 | | Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitnib and erlotinib. |
 | | Pao W*, Miller VA*, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. |
 | | Pao W and Miller VA. EGFR mutations, small molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions, J Clin Oncol 2005; 23:2556-2568. |
| www.mskcc.org /mskcc/html/57719.cfm (344 words) |
|